AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00392223
Drug: minocycline-placebo capsules
RxNorm normalized name: minocycline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
Trial: NCT00392223
Drug: Azithromycin microspheres-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
Trial: NCT00392223
Drug: Minocycline capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, PO, 100 mg daily for 8 weeks.
Trial: NCT00622505
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
Trial: NCT01396213
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsule
Trial: NCT04359199
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
Trial: NCT04411446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules of containing placebo orally given all at once. One dose.
Trial: NCT04359199
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody.
Trial: NCT00912496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
Trial: NCT00432263
Drug: Genotropin (PN-180,307) Somatropin
RxNorm normalized name: somatropin Cartridge [Genotropin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03224299
Drug: OCT - clear
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
Trial: NCT03224299
Drug: OCT- tinted
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
Trial: NCT03702400
Drug: Norepinephrine 5 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
Trial: NCT01036113
Drug: EZN-2208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
Trial: NCT03009474
Drug: CJ-30060
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
Trial: NCT03009474
Drug: Exforge tab 5/160mg, Crestor tab 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
Trial: NCT03101254
Drug: LY3022855
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
Trial: NCT01299753
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identically packed placebo
Trial: NCT02712411
Drug: HCP1303
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712411
Drug: HGP1201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712411
Drug: HIP1402
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04157257
Drug: TDF tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF tablet 300mg QD
Trial: NCT04157257
Drug: QL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL-007 tablets 200mg BID
Trial: NCT03331900
Drug: COR388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral capsule
Trial: NCT03331900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral capsule
Trial: NCT00952029
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00952029
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02076919
Drug: LHA510 Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
Trial: NCT02076919
Drug: LHA510 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used for masking purposes
Trial: NCT00952029
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03415282
Drug: RVT-501 0.5% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
Trial: NCT04409210
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
Trial: NCT00626418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00606177
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 0mg(4tablets)/day
Trial: NCT05872698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01225939
Drug: AZD8329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01225939
Drug: AZD8329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution
Trial: NCT01940848
Drug: STW5 (Iberogast, BAY98-7411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied orally over 28 days, 20 drops STW 5 three times daily
Trial: NCT01940848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied orally over 28 days, 20 drops placebo three times daily
Trial: NCT02807922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00817635
Drug: LCI699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 oral capsules
Trial: NCT00817635
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone oral capsules
Trial: NCT00817635
Drug: LCI699-matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699-matching placebo oral capsules
Trial: NCT00817635
Drug: Eplerenone-matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone-matching placebo oral capsules
Trial: NCT00633893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, twice daily, 12 months
Trial: NCT02333643
Drug: CLS003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00878618
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
Trial: NCT00878618
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
Trial: NCT02864095
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02616861
Drug: IW-1973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-1973 Tablet
Trial: NCT02616861
Drug: Matching Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT02624219
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT02624219
Drug: MF59 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Trial: NCT00649935
Drug: Azithromycin Tablets 600 mg
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, single dose fed
Trial: NCT00649935
Drug: Zithromax® Tablets 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, single dose fed
Trial: NCT02131324
Drug: DFD06 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01799161
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsule daily of Theophylline during 1st course, then adjusted dose
Trial: NCT01623336
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
Trial: NCT01623336
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
Trial: NCT01771666
Drug: 99technetium-sulfur colloid radiolabel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04520178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02741310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT02167516
Drug: glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
Trial: NCT02167516
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
Trial: NCT04889690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9% sodium chloride solution
Trial: NCT02281318
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
Trial: NCT00601848
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03493269
Drug: BAY1834845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered.
Trial: NCT02823548
Drug: Droglican
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
Trial: NCT00851240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00003728
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003728
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003728
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003728
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003728
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003728
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446223
Drug: Inggenol Mebutate 0.015%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182959
Drug: Avmacol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avmacol® tablets
Trial: NCT00307905
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homeopathic remedy
Trial: NCT00307905
Drug: Placebo remedy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical size, shape and taste of treatment medication
Trial: NCT02506192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets (2x5mg) daily for 8 weeks
Trial: NCT00650364
Drug: ProAmatine® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fasting
Trial: NCT00872781
Drug: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
RxNorm normalized name: Quinapril and Hydrochlorothiazide Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432458
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
Trial: NCT00216086
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid
Trial: NCT02682446
Drug: H pylori eradication
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
Trial: NCT02068625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with placebo for 7 days
Trial: NCT01435213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo (capsules) administered orally
Trial: NCT00038142
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
Trial: NCT01230619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
Trial: NCT00130741
Drug: CHT - herbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02490176
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were taken daily for 7 days
Trial: NCT03336450
Drug: SHP615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Trial: NCT03336450
Drug: MHOS/SHP615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHOS/SHP615
Trial: NCT04761237
Drug: Goal-directed fluid therapy (GDET)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
Trial: NCT00038142
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
Trial: NCT01955694
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
Trial: NCT01955694
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
Trial: NCT01955694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02934035
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01450124
Drug: Boswellic acids (BOSWELAN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
Trial: NCT01222936
Drug: LBH581
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
Trial: NCT01327677
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25-50 mcg every 20 minutes
Trial: NCT01327677
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mcg/demand dose with an 8 minute lock out
Trial: NCT01370694
Drug: MK-8808
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03257124
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 160mg per oral daily (1 cycle of 28 days)
Trial: NCT01370694
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01370694
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02909049
Drug: MEPIVACAÍNE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
Trial: NCT00877734
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered tid for 11 weeks
Trial: NCT03353480
Drug: Azithromycin Tablet manufactured in China
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Azithromycin Tablet manufactured in China
Trial: NCT03353480
Drug: Azithromycin Tablet manufactured in US
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Azithromycin Tablet manufactured in US
Trial: NCT03836768
Drug: DTRMWXHS-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTRMWXHS-12 capsules: 150 mg, 300 mg
Trial: NCT04004910
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
Trial: NCT01880658
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
Trial: NCT03107286
Drug: Tc-99M-MAG3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
Trial: NCT00732472
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day repeat dose
Trial: NCT04526912
Drug: VIB7734
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose
Trial: NCT04526912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single dose matched to VIB7734.
Trial: NCT03993119
Drug: Non-vitamin K antagonist oral anticoagulant
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K antagonist oral anticoagulant
Trial: NCT01085162
Drug: BMS747158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS747158 is a novel PET MPI agent labeled with Fluorine-18.